A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The study is being conducted to assess the safety 、tolerability 、 pharmacokinetics and
efficacy of SHR6390 combined with famitinib in the treatment of ER + / HER2- advanced breast
cancer.